1. In Vivo
  2. >>Leadership

A Day Job And A Gay Job: How OUTbio Is Connecting LGBTQ Biotech Executives

Networking Organization Now Has Branches Across The US, UK And Ireland

 
• By Chloe Kent

LGBTQ networking group OUTbio has gone from strength to strength since it was founded in 2015, from a small event attended by a handful of executives in Boston to a registered non-profit with affiliated groups across the US alongside international branches.

Pride flag billowing in the air
• Source: Shutterstock

“I always start by saying I have a day job and a gay job,” opened OUTbio founder Ramsey Johnson. By day, Johnson works as vice president of clinical operations of Aditum Bio. In his spare time, he runs the non-profit OUTbio, a growing LGBTQ professionals group for the biotech industry.

Since it was set up eight years ago, OUTbio has gone from being an informal organization to a fully-fledged non-profit with 501(c)(3) status in the US, recording attendance of well over 200 people at each of its regularly scheduled events in Boston and with around 1,800 estimated members in its local network

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By Jo Shorthouse

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

More from In Vivo

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.